Cytek Biosciences (CTKB) Cash from Investing Activities (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Cash from Investing Activities data on file, last reported at -$27.1 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 386.49% year-over-year to -$27.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.4 million (up 61.02% YoY) and the FY2025 annual result came in at $10.1 million, up 112.19% from the prior year.
• Cash from Investing Activities retreated to -$27.1 million in Q1 2026, from -$1.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $43.1 million in Q3 2023 to a low of -$168.9 million in Q1 2023.
• A 5-year average of -$14.7 million and a median of -$1.8 million in 2025 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 3849.91% in 2023, down 21550.51% in 2023.
• Tracing CTKB's Cash from Investing Activities over 5 years: stood at -$51.1 million in 2022, then jumped by 156.92% to $29.1 million in 2023, then tumbled by 318.24% to -$63.4 million in 2024, then surged by 97.1% to -$1.8 million in 2025, then slumped by 1370.09% to -$27.1 million in 2026.
• The last three Cash from Investing Activities figures came in at -$27.1 million (Q1 2026), -$1.8 million (Q4 2025), and $18.9 million (Q3 2025), per Business Quant data.